20hon MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
Hims & Hers Health shares jumped some 20% to a record high on Wednesday following the announcement that it acquired lab ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback